Shire/Noven Daytrana "Approvable" Pending Data Clarification
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA letter for the ADHD patch also requests additional information on post-marketing surveillance and post-marketing studies, the companies say.
You may also be interested in...
Daytrana ADHD Patch Response Submitted To FDA – Noven
The company says it has submitted a response to FDA’s “approvable letter” for the methylphenidate transdermal system.
Daytrana ADHD Patch Response Submitted To FDA – Noven
The company says it has submitted a response to FDA’s “approvable letter” for the methylphenidate transdermal system.
Shire Aims For Four Launches By Year-End
The firm plans to introduce the ADHD therapy NRP104 in the fourth quarter.